(Q37102767)

18 August 2017

1 reference

title

The role of the NFkappaB signalling pathway in cancer (English)

1 reference

18 August 2017

María Cortés Sempere

1

1 reference

18 August 2017

Vanesa Rodríguez Fanjul

series ordinal

2

1 reference

18 August 2017

Isabel Sánchez Pérez

series ordinal

3

1 reference

18 August 2017

Rosario Perona

series ordinal

4

1 reference

18 August 2017

language of work or name

1 reference

1 March 2008

1 reference

Clinical and Translational Oncology

18 August 2017

1 reference

18 August 2017

10

1 reference

18 August 2017

3

1 reference

18 August 2017

143-147

1 reference

https://scigraph.springernature.com/pub.10.1007/s12094-008-0171-3

18 August 2017

0 references

cites work

NF-kappaB controls cell growth and differentiation through transcriptional regulation of cyclin D1.

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12094-008-0171-3

Phase I study of two different schedules of bortezomib and pemetrexed in advanced solid tumors with emphasis on non-small cell lung cancer

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12094-008-0171-3

The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I study

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS12094-008-0171-3

The involvement of the candidate proto-oncogene NFKB2/lyt-10 in lymphoid malignancies.

21 January 2018

1 reference

12 December 2020

Bortezomib (VELCADE) in metastatic breast cancer: pharmacodynamics, biological effects, and prediction of clinical benefits

1 reference

12 December 2020

Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer

1 reference

12 December 2020

Characterization of target genes at the 2p15-16 amplicon in diffuse large B-cell lymphoma.

1 reference

12 December 2020

Molecular-cytogenetic comparison of mucosa-associated marginal zone B-cell lymphoma and large B-cell lymphoma arising in the gastro-intestinal tract

1 reference

12 December 2020

Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells.

1 reference

12 December 2020

Phase II trial of PS-341 in patients with renal cell cancer: a University of Chicago phase II consortium study

1 reference

12 December 2020

Small molecule inhibitors of IkappaB kinase are selectively toxic for subgroups of diffuse large B-cell lymphoma defined by gene expression profiling.

1 reference

12 December 2020

Phase I trial of the proteasome inhibitor bortezomib in combination with carboplatin in patients with platinum- and taxane-resistant ovarian cancer

1 reference

12 December 2020

The Rel/NF-kappaB family directly activates expression of the apoptosis inhibitor Bcl-x(L).

1 reference

12 December 2020

A phase II trial with pharmacodynamic endpoints of the proteasome inhibitor bortezomib in patients with metastatic colorectal cancer

1 reference

12 December 2020

The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance

1 reference

12 December 2020

The oncoprotein Bcl-3 directly transactivates through kappa B motifs via association with DNA-binding p50B homodimers

1 reference

12 December 2020

Characterization of a human REL-estrogen receptor fusion protein with a reverse conditional transforming activity in chicken spleen cells

1 reference

12 December 2020

Effects of IKK inhibitor PS1145 on NF-kappaB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells

1 reference

12 December 2020

Nuclear factor-kappaB in development, prevention, and therapy of cancer

1 reference

12 December 2020

Phase II trial of bortezomib for patients with advanced renal cell carcinoma

1 reference

12 December 2020

A phase II study of bortezomib in the treatment of metastatic malignant melanoma

1 reference

12 December 2020

Bortezomib: proteasome inhibition as an effective anticancer therapy

1 reference

12 December 2020

Integrating cell-signalling pathways with NF-kappaB and IKK function

1 reference

12 December 2020

BMS-345541 targets inhibitor of kappaB kinase and induces apoptosis in melanoma: involvement of nuclear factor kappaB and mitochondria pathways

1 reference

12 December 2020

The two NF-kappaB activation pathways and their role in innate and adaptive immunity

1 reference

12 December 2020

Oncogenes, tumor suppressors and p52 NF-κB

1 reference

12 December 2020

Signaling to NF-kappaB

1 reference

12 December 2020

NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation

1 reference

12 December 2020

10.1007/S12094-008-0171-3

Identifiers

DOI

1 reference

18 August 2017

1 reference